Riskpilot← Back to searchSign inGet full accessPICOMED AS
ASActiveOrg 962211631Brokelandsheia Gjerstadveien 398, 4993 SundebruWholesale of pharmaceutical and medical goods · NACE 4646Est. 199113 employeeswww.picomed.no
Revenue 2025
NOK 59,4M
+10% vs 2024
EBITDA margin
15.5%
+73% vs 2024
Equity ratio
67.7%
Financial strength
Net profit 2025
NOK 6,7M
+90% vs 2024
| Revenue | NOK 59,4M | +10% |
| EBITDA | NOK 9,2M | +73% |
| Net profit | NOK 6,7M | +90% |
| Total assets | NOK 32,1M | +37% |
| Equity | NOK 21,7M | +44% |
| Employees | 13 | — |
Legal name
PICOMED AS
Org number
962211631
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
15. august 1991
Share capital
NOK 330 000
Employees
13 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Styrets leder eller daglig leder hver for seg.
Address
Brokelandsheia Gjerstadveien 398, 4993 Sundebru
Website
www.picomed.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 21 752 | 22 885 | 20 327 | 19 841 | 25 501 | 28 918 | 29 759 | 33 522 | 37 826 | 36 137 | 53 242 | 53 138 | 44 660 | 43 532 | 44 733 | 48 835 | 54 031 | 59 411 |
| Staff expenses | −0 | −4 383 | −4 700 | −4 581 | −4 559 | −4 692 | −5 075 | −5 868 | −6 932 | −7 794 | −8 242 | −8 754 | −9 290 | −7 588 | −9 616 | −16 196 | −16 141 | −15 803 | −14 534 |
| EBITDA | 0 | 2 034 | 2 030 | 1 334 | 2 680 | 4 115 | 3 288 | 5 145 | 3 169 | 711 | 1 939 | 6 479 | 5 293 | 6 961 | 3 492 | 1 761 | 2 199 | 5 305 | 9 188 |
| Depreciation & amort. | −0 | −20 | −7 | −66 | −78 | −124 | −99 | −66 | −136 | −180 | −258 | −407 | −483 | −585 | −601 | −666 | −466 | −650 | −473 |
| EBIT | 0 | 2 014 | 2 022 | 1 268 | 2 602 | 3 991 | 3 189 | 5 079 | 3 033 | 531 | 1 681 | 6 071 | 4 810 | 6 376 | 2 892 | 1 095 | 1 733 | 4 654 | 8 715 |
| Net financials | 0 | −104 | −19 | 25 | 48 | 24 | 3 | 30 | −51 | −279 | −120 | −84 | −107 | 282 | −614 | −442 | 1 120 | −66 | −87 |
| Profit before tax | 0 | 1 910 | 2 003 | 1 293 | 2 650 | 4 015 | 3 191 | 5 108 | 2 983 | 252 | 1 561 | 5 987 | 4 703 | 6 658 | 2 277 | 653 | 2 853 | 4 589 | 8 628 |
| Tax | −0 | 540 | 569 | 373 | 751 | 1 141 | 908 | 1 390 | 731 | 74 | 384 | 1 385 | 1 055 | 1 457 | 648 | 130 | 459 | 1 060 | 1 935 |
| Net profit | 0 | 1 370 | 1 434 | 920 | 1 899 | 2 874 | 2 283 | 3 718 | 2 252 | 178 | 1 177 | 4 602 | 3 648 | 5 201 | 1 629 | 523 | 2 394 | 3 528 | 6 693 |
| Item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | — | 7 087 | 6 552 | 7 708 | 7 940 | 9 984 | 9 681 | 13 028 | 16 064 | 14 606 | 19 792 | 20 136 | 21 463 | 23 054 | 29 143 | 28 371 | 32 630 | 23 437 | 32 140 |
| Equity | — | 3 667 | 3 602 | 4 522 | 4 621 | 5 694 | 5 478 | 7 196 | 6 880 | 7 058 | 8 146 | 12 747 | 13 396 | 15 597 | 14 226 | 15 068 | 17 462 | 15 053 | 21 746 |
| Long-term debt | 0 | 0 | 0 | 0 | 7 | 0 | 9 | 9 | 26 | 8 | 891 | 976 | 659 | 432 | 8 281 | 7 367 | 6 746 | 793 | 585 |
| Short-term debt | 0 | 3 420 | 2 951 | 3 186 | 3 313 | 4 289 | 4 194 | 5 824 | 9 158 | 7 541 | 10 756 | 6 412 | 7 408 | 7 025 | 6 636 | 5 936 | 8 422 | 7 591 | 9 808 |
| Total debt | 0 | 3 420 | 2 951 | 3 186 | 3 319 | 4 289 | 4 203 | 5 832 | 9 184 | 7 549 | 11 647 | 7 388 | 8 067 | 7 458 | 14 918 | 13 303 | 15 168 | 8 384 | 10 393 |
EBITDA margin
15.5%
This company
15.8%
Market median
+2% vs market
20072025
Equity ratio
67.7%
This company
38.2%
Market median
+77% vs market
20072025
Return on equity
30.8%
This company
18.4%
Market median
+67% vs market
20072025
Net profit margin
11.3%
This company
8.1%
Market median
+40% vs market
20072025
Asset turnover
1.85×
This company
1.12×
Market median
+65% vs market
20072025
Debt / equity
0.48×
This company
0.62×
Market median
+23% vs market
20072025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
- Annual report 2007Filed via Brønnøysundsregistrene · Period 2007-01-01 – 2007-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SP Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
JT Chief Executive Officer | Chief Executive Officer | 2016 | — | — |
BS Deputy Member | Deputy Member | 2019 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2019 | — | — | |
| Chairman | 2025 | — | — | |
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2025 | — | — | |
| Chairman | 2019 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Abilia As | Company | 100.0% | 100.0% | 2024 |
Stimah As | Company | 44.4% | 44.4% | 2023 |
| Individual | 2.0% | 2.0% | 2023 | |
| Individual | 1.5% | 1.5% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Stimah As
PICOMED AS Board members of PICOMED AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Stian Pedersen | Chief Executive Officer | 0 companies |
| Jan Tore Stenersen | Chief Executive Officer | 0 companies |
| Bent-Håvard Sollid | Deputy Member | 0 companies |
| Dag Augon Isene | Board of Directors | 0 companies |
| Jon Erik Hansen Jullum | Board of Directors | 0 companies |
| Tove Emma Caroline Christiansson | Chairman | 0 companies |
| Morten Koren Stoltz | Board of Directors | 0 companies |
| Karl Johan Marcus Olsson | Board of Directors | 0 companies |
| Ole Roger Pedersen | Chairman | 0 companies |